| Name | Title | Contact Details |
|---|
Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.
AnHeart is a clinical stage global biopharmaceutical company developing novel precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
HemaQuest Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The DNA Repair Company is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.